You have read all your free articles, to continue reading subscribe to read the rest of this content.
Atrogi has received approval from the German authority BfArM to initiate a phase 1 study with their small molecule drug candidate ATR-258 in healthy volunteers and type 2 diabetics. The trial is expected to be completed by year end 2022 with the final report in Q1/2,2023. “Following extensivAlready a subscriber…
WntResearch has announces that the Danish regulatory authorities and the ethics committee have approved the protocol for the Phase 1b study with Foxy-5. The study will start immediately. With the Danish regulatory authorities and the ethics committee having approved the protocol for the previouAlready a subscriber Login You have read all your…
SynAct Pharma has announced results from the Phase 2a study of AP1189 in early rheumatoid arthritis (RA) patients experiencing severe disease activity. In this 4-week study, patients treated once-daily with 100 mg AP1189 achieved a significantly greater reduction in mean Clinical Disease ActivityAlready a subscriber Login You have read all…
The Regional Health Authorities in Norway has recently decided to reimburse patients who are included in the first expansion cohort in IMPRESS-Norway according to a pay-for-performance model. IMPRESS-Norway is a precision medicine trial that tests approved drugs on new indications based on genetiAlready a subscriber Login You have read all…
